Pharma-Bio Serv (PBSV) EBIAT (2016 - 2026)
Pharma-Bio Serv (PBSV) has disclosed EBIAT for 15 consecutive years, with -$102.0 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 100.63% year-over-year to -$102.0, compared with a TTM value of -$510003.0 through Oct 2025, up 51.18%, and an annual FY2025 reading of -$637662.0, up 18.0% over the prior year.
- EBIAT was -$102.0 for Q4 2025 at Pharma-Bio Serv, up from -$313877.0 in the prior quarter.
- Across five years, EBIAT topped out at $2.3 million in Q3 2021 and bottomed at -$4.9 million in Q4 2021.
- Average EBIAT over 5 years is -$67582.2, with a median of $128069.0 recorded in 2022.
- Peak annual rise in EBIAT hit 228.72% in 2021, while the deepest fall reached 3475.66% in 2021.
- Year by year, EBIAT stood at -$4.9 million in 2021, then surged by 107.01% to $341640.0 in 2022, then tumbled by 170.23% to -$239917.0 in 2023, then skyrocketed by 106.72% to $16111.0 in 2024, then plummeted by 100.63% to -$102.0 in 2025.
- Business Quant data shows EBIAT for PBSV at -$102.0 in Q4 2025, -$313877.0 in Q3 2025, and -$103833.0 in Q2 2025.